Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors.
Austin RJ, Lemon BD, Aaron WH, Barath M, Culp PA, DuBridge RB, Evnin LB, Jones A, Panchal A, Patnaik P, Ramakrishnan V, Rocha SS, Seto P, Sexton K, Strobel KL, Wall R, Yu S, Yu TZ, Law CL, Baeuerle PA, Wesche H. Austin RJ, et al. Mol Cancer Ther. 2021 Jan;20(1):109-120. doi: 10.1158/1535-7163.MCT-20-0061. Epub 2020 Nov 17. Mol Cancer Ther. 2021. PMID: 33203731
Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors.
Molloy ME, Austin RJ, Lemon BD, Aaron WH, Ganti V, Jones A, Jones SD, Strobel KL, Patnaik P, Sexton K, Tatalick L, Yu TZ, Baeuerle PA, Law CL, Wesche H. Molloy ME, et al. Among authors: austin rj. Clin Cancer Res. 2021 Mar 1;27(5):1452-1462. doi: 10.1158/1078-0432.CCR-20-3392. Epub 2020 Dec 1. Clin Cancer Res. 2021. PMID: 33262134
HPN328, a Trispecific T Cell-activating Protein Construct Targeting DLL3-Expressing Solid Tumors.
Molloy ME, Aaron WH, Barath M, Bush MC, Callihan EC, Carlin K, Cremin M, Evans T, Gamez Guerrero M, Hemmati G, Hundal AS, Lao L, Laurie P, Lemon BD, Lin SJ, O'Rear J, Patnaik P, Sotelo Rocha S, Santiago L, Strobel KL, Valenzuela LB, Wu CH, Yu S, Yu TZ, Anand BS, Law CL, Sun LL, Wesche H, Austin RJ. Molloy ME, et al. Among authors: austin rj. Mol Cancer Ther. 2024 Apr 27. doi: 10.1158/1535-7163.MCT-23-0524. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38670552
Oncogenic drivers dictate immune control of acute myeloid leukemia.
Austin RJ, Straube J, Halder R, Janardhanan Y, Bruedigam C, Witkowski M, Cooper L, Porter A, Braun M, Souza-Fonseca-Guimaraes F, Minnie SA, Cooper E, Jacquelin S, Song A, Bald T, Nakamura K, Hill GR, Aifantis I, Lane SW, Bywater MJ. Austin RJ, et al. Nat Commun. 2023 Apr 14;14(1):2155. doi: 10.1038/s41467-023-37592-9. Nat Commun. 2023. PMID: 37059710 Free PMC article.
Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis.
Kumar R, Bunn PT, Singh SS, Ng SS, Montes de Oca M, De Labastida Rivera F, Chauhan SB, Singh N, Faleiro RJ, Edwards CL, Frame TCM, Sheel M, Austin RJ, Lane SW, Bald T, Smyth MJ, Hill GR, Best SE, Haque A, Corvino D, Waddell N, Koufariotis L, Mukhopadhay P, Rai M, Chakravarty J, Singh OP, Sacks D, Nylen S, Uzonna J, Sundar S, Engwerda CR. Kumar R, et al. Among authors: austin rj. Cell Rep. 2020 Feb 25;30(8):2512-2525.e9. doi: 10.1016/j.celrep.2020.01.099. Cell Rep. 2020. PMID: 32101732 Free PMC article.
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW. Austin RJ, et al. Leukemia. 2020 Apr;34(4):1075-1089. doi: 10.1038/s41375-019-0638-y. Epub 2019 Nov 15. Leukemia. 2020. PMID: 31732720 Free PMC article.
40 results